[1] Thway K,
Noujaim J, Jones RL, et al. Dermatofibrosarcoma protuberans: pathology,
genetics, and potential therapeutic strategies[J]. Ann Diagn Pathol, 2016,
25:64-71. DOI: 10.1016/j.anndiagpath.2016.09.013.
[2] Acosta AE, Vélez CS. Dermatofibrosarcoma
protuberans[J]. Curr Treat Options Oncol, 2017, 18(9):56. DOI:
10.1007/s11864-017-0498-5.
[3] Llombart B, Serra-Guillén C, Monteagudo
C, et al. Dermatofibrosarcoma protuberans: a comprehensive review and update on
diagnosis and management[J]. Semin Diagn Pathol, 2013, 30(1):13-28. DOI:
10.1053/j.semdp.2012.01.002.
[4] Karanian M, Pérot G, Coindre JM, et al.
Fluorescence in situ hybridization analysis is a helpful test for the diagnosis
of dermatofibrosarcoma protuberans[J]. Mod Pathol, 2015, 28(2):230-237. DOI:
10.1038/modpathol. 2014.97.
[5] 赵新美,李明,夏钰弘,等.手部不确定性软组织肿瘤的临床及超声表现[J].中国医学影像技术,2015,31(8):1263-1266.
DOI:10.13929/j.1003-3289.2015.08.040.
[6] Voth H, Landsberg J, Hinz T, et al.
Management of dermatofibrosarcoma protuberans with fibrosarcomatous
transformation: an evidence-based review of the literature[J]. J Eur Acad
Dermatol Venereol, 2011, 25(12):1385-1391. DOI: 10.1111/j.1468-3083.
2011.04141.x.
[7] Kreicher KL, Kurlander DE, Gittleman HR,
et al. Incidence and survival of primary dermatofibrosarcoma protuberans in the
United States[J]. Dermatol Surg, 2016, 42 Suppl 1:S24-S31. DOI: 10.1097/DSS.
0000000000000300.
[8] Criscione VD, Weinstock MA. Descriptive
epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to
2002[J]. J Am Acad Dermatol, 2007, 56(6):968-973. DOI:
10.1016/j.jaad.2006.09.006.
[9] 韩晓明.超声诊断隆突性皮肤纤维肉瘤1例[J].临床超声医学杂志,2020,22(1):37.
DOI:10.3969/j.issn.1008-6978. 2020.01.013.
[10] 沈文佳,刘艳萍,陈卉,等.隆突性皮肤纤维肉瘤的超声表现[J].中国超声医学杂志,2013,29(10):947-950.
DOI:10.3969/j.issn.1002-0101.2013.10.024.
[11] 吴共发,邱丽浈,郑秋华,等.隆突性皮肤纤维肉瘤超声及临床病理分析[J].中国超声医学杂志,2016,32(4):380-382.
DOI:10.3969/j.issn.1002-0101.2016.04.031.
[12] 陈香梅,沈宇宙,刘俐.隆突性皮肤纤维肉瘤的超声表现[J].中国CT和MRI杂志,2018,16(8):136-137.
DOI:10.3969/j.issn.1672-5131.2018.08.042.
[13] 赵胜男,杨冉,田思雨,等.隆突性皮肤纤维肉瘤的超声诊断[J/CD].中华医学超声杂志(电子版),2021,18(1):30-32. DOI:10.3877/cma.j.issn.1672-6448.2021.01.007.
[14] Shin YR, Kim JY, Sung MS, et al.
Sonographic findings of dermatofibrosarcoma protuberans with pathologic
correlation[J]. J Ultrasound Med, 2008, 27(2):269-274. DOI:
10.7863/jum.2008.27.2.269.
[15] Lee SJ, Mahoney MC, Shaughnessy E.
Dermatofibrosarcoma protuberans of the breast: imaging features and review of
the literature[J]. AJR Am J Roentgenol, 2009, 193(1):W64-69. DOI:
10.2214/AJR.08.2141.
[16] Zou MH, Huang Q, Yang T, et al. Role of
ultrasound in the diagnosis of primary and recurrent dermatofibrosarcoma
protuberans[J]. BMC Cancer, 2021, 21(1):909. DOI: 10.1186/s12885-021-08476-2.
[17] Bae SH, Lee JY. Imaging features of
breast dermatofibrosarcoma protuberans in various modalities including FDG-PET
CT[J]. Iran J Radiol, 2016, 13(2):e33916. DOI: 10.5812/iranjradiol.33916.
[18] 江泽良,丁辉,林萍,等.高频彩色多普勒超声对周围浅表血管瘤的诊断价值[J].国际医药卫生导报,2012,18(21):3105-3107.
DOI:10.3760/cma.j.issn.1007-1245.2012. 21.007.
[19] Saiag P, Grob JJ, Lebbe C, et al.
Diagnosis and treatment of dermatofibrosarcoma protuberans. European
consensus-based interdisciplinary guideline[J]. Eur J Cancer, 2015,
51(17):2604-2608. DOI: 10.1016/j.ejca.2015.06.108.
|